Content available at: https://www.ipinnovative.com/open-access-journals

Indian Journal of Clinical Anatomy and Physiology

Journal homepage: https://www.ijcap.org/

Review Article

Organoids and 3D tissue engineering: Advances, applications and future directions- A review

Nandini Sharma[1]*, Anupama V. Betigeri[2], Pari Mittal[3], Vithalkumar Malleshi Betigeri[4]

[1]Dept. of Anatomy, Manav Rachna Dental College, SDS. MRIIRS, Faridabad, Haryana, India
[2]Dept. of Physiology, Manav Rachna Dental College, SDS. MRIIRS, Faridabad, Haryana, India
[3]Manav Rachna Dental College, SDS. MRIIRS, Faridabad, Haryana, India
[4]Dept. of CTVS-1, Jawahar Lal Nehru Marg, Govind Ballab Pant Institute of Postgraduate Medical Education and Research, New Delhi, India

Abstract

In biomedical investigation, organoids and three-dimensional (3D) tissue designing have become the excellent apparatuses that offer observations in human organ development, disease modeling and regenerative pharmaceuticals, which were unthinkable. The comprehensive survey analyses current advancements in 3D tissue designing and organoid innovations, where it represents different techniques, applications and complications. Along with future investigation of plausible outcomes and ethical reflection, we moreover highlight how these advances might alter predictive disclosure and customized medication. An organoid is a multicellular structure developed through 3D in vitro culture and can be derived from primary stem cells, induced pluripotent stem cells (iPSCs), or embryonic stem cells (ESCs). Organoids are valuable tools for studying tumor models and stem cell biology due to their ability to self-replicate and proliferate while preserving the physiological structure and function of their donor tissues. Patient-derived organoids fill in the conventional crevices in the models and have the capacity for personalized treatment, translational medicine, tumor sedation screening, and cancer demonstration in clinical inquiry about Organoids delivered from patients may serve as a profitable instrument for exploring the atomic pathophysiology of gallbladder tumors and creating solutions tailored to the need of each patient.

Keywords: Organoids, 3D tissue designing, Regenerative medication, Infection demonstration, Bioprinting, Pluripotent stem cells

Received: 12-09-2025; **Accepted:** 14-01-2026; **Available Online**: 10-2-2026

1. Background

Organoids are stem cell-derived, three-dimensional, self-organizing substances that duplicate particular organ plans and capacities. When compared to ordinary 2D cell societies, they offer a show that is more physiologically fitting. Proliferations in tissue designing and stem cell science have driven the improvement of organoid innovation, empowering researchers to make organ-like structures that closely resemble them in vivo environment. In the field of biomedical sciences, the combination of organoid innovation and 3D tissue designing is a major development. In spite of the fact that 3D tissue building centers on building complex tissue builds that imitate local organ engineering, organoids are three-dimensional substances are made from stem cells that mirror specific organ capacities outlined in **Figure 1**. These advancements open up new hopes for demonstrating ailments, investigating human science, and customising treatment plans.[1] The development of organoid technology and 3-D tissue engineering has brought about a remarkable revolution in the field of tissue engineering. These developments present unprecedented likelihood for modelling diseases, knowing human biology and creating trail, blazing treatment plans.

Three-dimensional (3D) bioprinting is an exciting interdisciplinary field that unites computer science, materials science, biology, medicine, and mechanical engineering. It holds significant importance for precisely controlling the distribution of cells and their surrounding microenvironment in tissue and organ engineering. The development of 3D bioprinting has progressed through three distinct stages: the

Corresponding author: Nandini Sharma
Email: nandinisharma.sds@mriu.edu.in

http://doi.org/10.18231/j.ijcap.13333.1769488766

use of non-biocompatible materials, the introduction of biocompatible and biodegradable materials, and ultimately, the incorporation of living cells. Recently, human organs such as the heart, kidneys, and lungs have been successfully engineered in vitro, offering new prospects for organ repair and transplantation.

2. Review

Organoids are small, self-assembling tissue structures that mirror particular organs composition and capacities. By and large delivered from pluripotent or grown-up stem cells, they can be developed to take up a variety of organs, including the intestines, liver and brain.[1] Careful control will be vital for almost all tissues joined to the utilization of stem cells, the advancement of organoids and the commercialization of made tissues.[2] Setting a new topic for future consideration, researchers innovative work illustrated that using intestinal stem cells to make organoids was workable.[3]

Tissue building (outlined in **Figure 2**) is a sub-branch of regenerative pharmaceutical that targets to repair, replace or recover tissues or organs. This is fulfilled through the interpretation of standards of material science, chemistry and science combined with the standards of materials building and cell transplantation. The objective of this technique is to mirror local tissues that can work as replacement substances with helpful benefits to regenerate harmed tissues, work as a stage to think about medical cytotoxicity at a cellular and atomic level, and show infection under research facility conditions. With these advancements, 3D models with ECM-mimicking proteins might sum up the microarchitecture and a useful cellular environment of the local organ. In later a long time, organ-on-the-chip innovation has been picking up weight due to its capacity to recreate organ-level physiology by reproducing the multicellular associations and interfaces, vascular perfusion, mechanical signals, and chemical gradients beneath exceedingly controlled environments.



Figure 1: Diagram of organoid development from stem cells.[1]



Figure 2: 3D Tissue show frameworks.4



Figure 3: 3D tissue models[2]

The biotechnology and arrangement of complex biomimetic tissue for showing frameworks include considering a few plan characteristics and frameworks. A 3D tissue show plan can be created by making spheroids and organoids; be that as it may, whereas being able to give a 3D microenvironment, a major challenge with these frameworks is the need for vasculature, which is fundamental in giving oxygen and supplements, while removing metabolic waste from cells. A platform that mimics the ECM is created through strategies such as 3D bioprinting, electrospinning, and solvent casting/particulate filtering (SCPL) to make porous structures that house the cells, development variables, vasculature, and transcription variables. The choice of biomaterial to create the ECM is crucial.[4]

Developments in these areas will make it achievable to make more complex and exact models for utilisation in clinical and research areas. The developments of these advances will make ethical and legal issues more vital. Guaranteeing capable advancement and usage of these innovations will require sticking to moral standards and administrative needs. A major issue is coordinating 3D tissue designing and organoid innovation into clinical use. For these

innovations to be effectively coordinated into healthcare settings, it is important that they be assured in terms of security, viability, and reproducibility.[5] The aim of future organoid and 3D tissue building investigations will likely be to make tissue models more applicable and complicated. Advances in fabric science, stem cell science and bioprinting are now being thought to affect this teaching encouragement.[6]

In a similar way, liver organoids have made it less demanding to think about liver conditions like fibrosis and hepatitis.[7] While comparing them to 2D models more accurate details about the diseases can be seen.

3. Personalized Medicine

Customised pharmaceutical is one of the most promising applications of organoid innovation. Organoids created from patients permit the testing of individualized pharmaceutical reactions and helpful approaches, giving a tailored course of treatment. Since it empowers the use of medicines based on each patient profiles, this technology has the potential to enhance treatment outcomes.

4. 3D Tissue Models

Making scaffold-based or scaffold-free structures that mimic the complexity of natural tissues is known as 3D tissue engineering, illustrated in **Figure 3**.

Scaffold material determination is crucial for 3D tissue engineering. To enhance tissue advancement and cell development, apparatus similar to hydrogels, characteristic extracellular matrix components, and biodegradable polymers are regularly used.[8] Organoids offer a solid establishment for stimulating intricate illnesses. For example, the examination of neurological conditions similar to microcephaly and Zika infection conditions has been conducted in using brain organoids.[9] Operations for 3D towel structure are colourful and include the enhancement of complicated organ models and skin grafts. In any case, there are still major obstacles to overcome, similar as getting acceptable vascularization, guaranteed tissue integration and protecting tissue viability over the long term.[10]

These strategies aim to duplicate the cellular medium and extracellular matrix needed for tissue function.

The mechanical characteristics, biocompatibility, and general success of tissue engineering projects are affected by the choice of appartuses. In order to achieve clinical interpretation and development of the tech, many challenges must be taken care of.

5. Integration of Organoids and 3D Towel Engineering

The distance and complexity of tissue models can be expanded by combining 3D tissue engineering with organoid advances. For instance, putting organoids in extraordinarily outlined platforms can fasten their advancement and make it easy to construct-multi-organ system for more careful illness demonstration.[11] Ethical and religious endeavour may arise regarding the use of(decellularized) human tissues , particularly cadaveric tissues — as scaffold components .Artificial scaffolds , zoogenic scaffold or decellularised tissues from living donors are preferred.[12] This tech depends intensively on strategies responsible for hydrogel application, electro- spinning, and bioprinting. Live tracking of electrical activity in cardiac tissues is helping researchers find the mechanisms behind arrhythmias and evaluate the efficacy of antiarrhythmic drugs. One particularly encouraging approach involves integrating 3D cardiac tissue models with real-time monitoring tools. For example, scientists have employed 3D cardiac tissue constructs to study electrical conduction abnormalities and the effects of pharmacological agents on cardiac function.[13] Liver organoids in combination with bioengineered fabrics have appeared distended survivability and utility, showing a precious demonstrate for investigation on liver clutters and liver transplantation.[14] These accomplishments sprinkled the likelihood of intertwining these inventions to deliver further more important, therapeutics and research instruments.

To fully realize the potential of these inventions and overcome these obstructions, interrogation about it and its enhancement must continue.

The Diversity and complexity of organoids have conscisciously expanded in lately a long time, making them irreplaceable research instruments. These days, organoids are more intricate at reproducing the complex structure and operations of tissues. Cerebral organoids, for instance, have showed to be suitable to reenact neurological disarranges and brain advancement in extraordinary complexity, demonstrating the creation of neuronal systems and synaptic associations. Similarly, by mirroring the intestinal epithelium and related affections, gastrointestinal organoids have been employed to show gastrointestinal disorders, counting Crohn's illness and colorectal cancer.

The consideration of complicated infections and ingrain issues has served immensely from the use of organoids. CRISPR/ Cas9 invention is one recent enhancement that makes it plausible to insert particular genetic mutations into organoids, permitting for a more essential understanding of hereditary illnesses.[15] This capability has demonstrated to be particularly important in the modelling of cancer, as organoids obtained from patient’s tumours give a customized strategy for inquiring about searching tumour biology and treatment responses.[16] Organoids have demonstrated a part of guarantee for use in drug testing. Organoids created from patients give a stage for assessing the toxicity and efficacy of drugs in an environment which is similar to the patient’s own tissues, which may result in more individualise treatment, plans . Novel, pharmacology, responses, and cancer, and other disorders have already been found due to the strategy.

The microfluidic reenactment of in vivo conditions has got to organ- on-a-chipmicro-scale systems copying the mortal body for both drug testing and disease modelling with the main aim of increasingly, replacing animal models. Organs- on-a-chip are made capable of reproduction by the combining of the advanced data in cellco-cultures, stem cells, genome changing, sesnors, 3D printing and microfluidics. Organs- on-a-chip stimulate the work of tissues and organs; they're erected joining differing tissues into 3D systems on which bio and physical powers are associated in the setting of reenacting in vivo conditions. Other than, organs on-a-chip (without any mistakes) can be combined making a body- on-a-chip; productive systems that allow to review organ interactions, which determine human body complexity. The body- on-a-chip is an efficient procedure for the evaluation of conservation, spread, metabolization, and elimination (ADME) of medicines underneath testing.[17]

Organoid technology is increasingly being applied to cancer tissue engineering, including modeling tumour formation processes or making tumour biobanks. The combination of CRISPR – Cas9- mediated gene formatting and organoid technology has greatly advanced the study of potential driver genes involved in tumour formation, these in vitro models have handed precious insight into colorful cancers, including brain, gastrointestinal, and liver cancers.[18]

6. Limitations of Organoid Technology

They join the limited improvement and cell contrasting qualities of the right presently made in vitro organoids when considered to replace the in vivo organs, the unsatisfactory size of made organoids for organ transplantation, and the poor reconstructibility for enormous production and the lacking of the vascular, nervous and immune system to summarize the in vivo tissue interaction. At present, various organoids are obtained from the iPSCs. iPSCs that are not totally isolated have the potential to shape tumors such as teratomas. Generally, iPSCs can create various byproducts, such as mesenchymal cells, during the inception process. Moreover, most iPSC-derived tissues are still at the fetal organization and are less mature than grown-up tissues. In this way, the recognizing verification and purification of the grown-up stem cells to deliver distinctive organoids is still an imperative strategy for making organoids at the present times. Moreover, the conditions for organoid cultures are still not totally upgraded, which can result in a changed degree of reproducibility under the same conditions. This was examined in a study contrasting the cell populations of individual brain organoid delivered by assorted techniques, which revealed that the organoids were as it were exceedingly reproducible underneath one condition but different essentially in other conditions. Finally, the biological activities in organs usually require the crosstalk between parenchymal cells and immune cells or even cells of the peripheral nervous systems. However, most of the currently generated organised still lack cells of both immune system and the peripheral nervous system.This existing deficiency stops organoids from completely showing the totally natural characteristics of their in vivo accomplices for modeling both developmental and pathological processes.

3D tissue models, counting those made through bioprinting and progressed biomaterials, have made noteworthy strides in imitating tissue usefulness and intuitive. Tissue models with complicated topologies may presently be accurately developed since of headways in bioprinting advances. The controlled statement of cells and biomaterials made conceivable by strategies like inkjet and extrusion-based printing makes it simpler to make tissues that closely take after normal structures. Hydrogels and engineered polymers are illustrations of framework materials that are utilized to give bolster and biochemical prompts vital for tissue arrangement and work. In 3D tissue designing, successful vascularization is still troublesome to accomplish. The displaying of blood stream and nourishment changes has been progressed by later improvements in the joining of vascular systems into tissue models, expanding the model's significance for the think about of physiological and pathological processes. Besides, a more comprehensive stage for disease modelling and treatment testing is given by organ-on-a-chip advances, which have combined various tissue types to reproduce organ intelligent and systemic reactions. The utilization of 3D tissue models in the investigate of numerous infections, counting cancer and cardiovascular issues, has been demonstrated. These models give a more physiologically fitting system for comprehending the mechanisms behind illness and surveying the viability of medicines.[18]

7. Clinical Implications

The future of organoids and 3D tissue models is promising, with several key areas poised for further development.

1. **Integration with artificial intelligence:** By analyzing data from organoid and 3D tissue model experiments, artificial intelligence (AI) and machine learning can improve model design and prediction accuracy. AI-driven methods could improve the interpretation of complex biological data and speed up discoveries.
2. **Clinical translation**: Although 3D tissue models and organoids have demonstrated great potential, integrating these technologies into clinical practice is not devoid of obstacles. Integrating these models into widespread clinical use requires addressing regulatory problems, standardizing techniques and validating model correctness.
3. **Complex multi-organ systems:** The creation of multi-organ models, which replicate the interactions between many tissues and organs, will lead to a deeper understanding of systemic disorders and their therapeutic outcomes. These models, which provide insights into how medicines affect many organ

systems simultaneously, have the potential to transform personalized medicine and drug testing.

4. **Ethical and accessibility considerations**: It is crucial to address ethical issues with the use of organoids and 3D tissue models as the area develops. Ensuring the accessibility of these technologies in various academic and clinical contexts is imperative to foster egalitarian improvements and optimize their advantages.

8. Conclusion

Significant developments in biomedical research and regenerative medicine can be attributed to organoids and 3D tissue engineering. These technologies provide insightful information about disease modelling, organ development, and therapeutic approaches. Even while there are still obstacles to overcome, more research and innovations in the field may revolutionize personalized medicine and enhance patient outcomes. Organoids and three-dimensional tissue engineering constitute a significant advance in biomedical research and regenerative medicine, providing rich possibilities for comprehending human biology and creating novel therapeutic approaches. The review emphasizes on the significant advancements made in these fields while highlighting both the obstacles still to overcome and their revolutionary potential.

9. Source of Funding

None.

10. Conflict of Interest

None.

References

1. Clevers H. Modelling development and disease with organoids. *Cell*. 2016;165(7):1586-97. doi:10.1016/j.cell.2016.05.082
2. Xie R, Pal V, Yu Y, et al. A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications. *Biomaterials*. 2024;304:122408. https://doi:10.1016/j.biomaterials.2023.122408
3. Sato T, Vries RG, Snippert HJ. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature*. 2011;491(7427):256-60. https://doi:10.1038/nature115 36
4. Shyam R, Reddy LVK, Palaniappan A. Fabrication and characterization techniques of in vitro 3D tissue models. *Int J Mol Sci*. 2023;24(3):1912. https://doi:10.3390/ijms24031912
5. Samorezov JE, Alsberg E. Spatial regulation of controlled bioactive factor delivery for bone tissue engineering. *Adv Drug Deliv Rev.* 2015;84:45-67. https://doi:10.1016/j.addr.2014.11.018.
6. Homan KA, Gupta KM, West JL, et al. Organoid-based 3D cell culture models. *Methods Cell Biol*. 2016;126:1-29. https://doi:10.1016/bs.mcb.2016.02.024.
7. Huch M, Gehart H, Van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. *Cell Stem Cell.* 2015;16(1):11-24. https://doi:10.1016/j.stem.2015.01.016.
8. Kretlow JD, Mikos AG. Critical aspects of scaffolding in regenerative medicine. *Tissue Eng Part B Rev.* 2008;14(1):10-28. https;//doi:10.1089/teb.2007.0280.
9. Lancaster MA, Polard MN, Lindman CA. Cerebral organoids model human brain development and microcephaly. *Nature.* 2013;501(7467):373-9. https://doi:10.1038/nature12517.
10. Nichol JW, Koshy SK, Bae CM, Johnson CM, Mooney DJ. Cell-laden hydrogels for tissue engineering. *Biomaterials.* 2009;30(30):5737-46. https://doi:10.1016/j.biomaterials.2009.05.064
11. Ranga A, Gjorevski M, Lutolf CM, et al. Tissue morphogenesis in 3D cell culture. *Biomaterials.* 2014;35(10):3129-43. https://doi:10.1016/j.biomaterials.2014.04.033
12. de Kanter AJ, Jongsma KR, Verhaar MC, Bredenoord AL. The ethical implications of tissue engineering for regenerative purposes: A systematic review. *Tissue Eng Part B Rev*. 2023;29(2):167-87. https://doi:10.1089/ten.TEB.2022.0033
13. Wang X, Zhang Y, Zhang X. Bioprinting in tissue engineering and regenerative medicine. *Biomaterials*. 2019;257: 120209.https://doi:10.1016/j.biomaterials.2020.120209.
14. Zhang JC, Meyer SR, O'Meara MJ. Liver organoids for studying liver disease and drug discovery. *J Hepatol*. 2023;78(5):998-1006.https://doi:10.1016/j.jhep.2023.01.019.
15. Koo BK, Sasselli V, Clevers H. Retroviral gene expression control in primary organoid cultures. *Curr Protoc Stem Cell Biol*. 2013;27:5A.6.1-5A.6.8. https://doi:10.1002/9780470151808.sc05 a06s27.
16. Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering stem cell organoids. *Cell Stem Cel*l. 2016;18(1):25-38. https://doi:10.1016/j.stem.2015.12.005.
17. Saorin G, Caligiuri I, Rizzolio F. Microfluidic organoids-on-a-chip: The future of human models. *Semin Cell Dev Biol*. 2023;144:41-54. https;//doi:10.1016/j.semcdb.2022.10.001
18. He J, Zhang X, Xia X. Organoid technology for tissue engineering. *J Mol CellBiol*. 2020;12(8):569-79. https://doi:10.1093/jmcb/mjaa012.

Cite this article: Sharma N, Betigeri AV, Mittal P, Betigeri VM. Organoids and 3D tissue engineering: Advances, applications and future directions- A review. *Indian J Clin Anat Physiol*. 2025;12(4):158-162.